Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Polydipsia, Diabetes insipidus, and Polyuria. 15 total HPO annotations.
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 3:09 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Organ System |
|---|
Phenotype Count |
|---|
Example Features |
|---|
Digestive system | 3 | Vomiting, Feeding difficulties in infancy, Constipation |
Brain and nerves | 3 | Seizure, Irritability, Intellectual disability |
Growth and development | 2 | Short stature, Failure to thrive |
Metabolism | 1 | Unexplained fevers |
Hormones | 1 | Diabetes insipidus |
Hereditary nephrogenic diabetes insipidus (NDI). Individuals with NDI typically have polyuria and polydipsia. However, in infants, polydipsia and polyuria are often unappreciated or unremarkable. Infants usually present with poor feeding, poor weight gain, and irritability. Infants are eager to suck but may vomit during or shortly after feeding. Dehydration is evident with dryness of the skin, loss of normal skin turgor, recessed eyeballs, increased periorbital folding, depression of the anterior fontanel, and a scaphoid abdomen. Intermittent high fever is a common complication of dehydration, predominantly in very young children. Seizures can occur but are rare and most often seen during therapy, particularly if rehydration proceeds too rapidly.
Source: GeneReviews — "Hereditary Nephrogenic Diabetes Insipidus"
AVPR2 encodes arginine vasopressin receptor 2 (371 aa). G-protein-coupled receptor for arginine vasopressin, an antidiuretic that promotes renal water reabsorption. Highest expression in Adipose Subcutaneous (14.3 TPM) and Kidney Medulla (10.8 TPM).
Diabetes insipidus, nephrogenic, X-linked is associated with mutations in the AVPR2 gene on chromosome X.
The AVPR2 protein participates in AVPR2 bind desmopressin, Defective AVP mutants do not bind AVPR2, and AVPR1A,2 bind AVPR antagonists pathways.
AVPR2 is classified as a druggable target (Druggable Genome and G Protein Coupled Receptor categories) with score 4.7.
AVPR2. A minority of AVPR2 pathogenic variants result in partial insensitivity to AVP or DDAVP®, and disease onset may be later in childhood. At present, 18 AVPR2 pathogenic variants resulting in partial NDI have been reported. These include:
, , , ; reach the cell surface with impaired ligand capacity and partial AVP/DDAVP binding. See review in ,
; decreased ligand-binding affinity and decreased coupling to Gs
; decreased number of cell surface AVPR2 receptors
and ; reduced cell surface expression and decreased binding affinity for AVP
, , and ; impaired intracellular trafficking
; decreased AVP binding most likely due to conformational changes
and (splice site); identified in individuals with partial NDI
Source: GeneReviews — "Hereditary Nephrogenic Diabetes Insipidus"
Hereditary nephrogenic diabetes insipidus (NDI) should be suspected in an individual with the following clinical and laboratory findings.
Clinical
Polyuria (excessive urine production)
Polydipsia (excessive drinking)
Family history of NDI
Note: In the first few months after birth, polyuria and polydipsia may not be immediately noticed; infants with NDI usually present with poor feeding, failure to thrive, and irritability.
Laboratory
Source: GeneReviews — "Hereditary Nephrogenic Diabetes Insipidus"
Diabetes insipidus is the excretion of abnormally large volumes (i.e., 50 mL/kg body weight in 24 hours) of dilute urine (i.e., specific gravity 1.010 or osmolality 300 mOsm/kg). In addition to hereditary nephrogenic diabetes insipidus (NDI), causes of diabetes insipidus include the following:
Source: GeneReviews — "Hereditary Nephrogenic Diabetes Insipidus"
Genetic testing for AVPR2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for diabetes insipidus, nephrogenic, X-linked has been reported in the published literature.
No approved treatments are currently available for diabetes insipidus, nephrogenic, X-linked. The disease remains an area of unmet medical need.
To establish the extent of disease in an individual diagnosed with hereditary nephrogenic diabetes insipidus (NDI), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 2.
Recommended Evaluations Following Initial Diagnosis in Individuals with Hereditary Nephrogenic Diabetes Insipidus
System/Concern | Evaluation | Comment
| Kidney ultrasound exam | To evaluate for hydronephrosis, dilatation of urinary tract, megacystis
| • Consultation w/clinical geneticist /or genetic counselor
Developmental eval in children w/history of episode of severe dehydration or delay in diagnosis
|
Management is usually best accomplished by a team consisting of a nutritionist, a pediatric (or adult) nephrologist or endocrinologist, and a clinical geneticist. General management. The essence of management is the provision of free access to drinking water and to toilet facilities. Infants, who are naturally unable to seek out water when thirsty, must be offered water between regular feedings. Children and adults who are heavy sleepers may need to be awakened at night by a family member or an alarm clock in order to drink water and to urinate. As long as an individual's thirst mechanism remains intact and the person is otherwise well, these measures prevent hypernatremic dehydration.
Source: GeneReviews — "Hereditary Nephrogenic Diabetes Insipidus"
Water intake must not be restricted.
Source: GeneReviews — "Hereditary Nephrogenic Diabetes Insipidus"
In a few individuals with a milder AVPR2 pathogenic variant resulting in a partial response to AVP and DDAVP®, high doses of DDAVP® in combination with a thiazide diuretic significantly decreased urinary volume . Effectiveness and safety of this treatment in partial NDI need to be explored further. Because of the known gastrointestinal safety of selective cyclooxygenase (COX)-2 inhibitors compared to nonselective COX inhibitors (e.g., indomethacin), use of these drugs has been proposed for the treatment of hereditary NDI. The effectiveness of a specific COX-2 inhibitor in decreasing free water losses was demonstrated in male infants with hereditary NDI .
Source: GeneReviews — "Hereditary Nephrogenic Diabetes Insipidus"
View trials for diabetes insipidus, nephrogenic, X-linked
There are no published guidelines available on recommended surveillance for children or adults with hereditary NDI. The frequency of follow up should take into consideration the medications being used and compliance with medications and diet recommendations.
Table 3.
Recommended Surveillance for Individuals with Hereditary Nephrogenic Diabetes Insipidus
System/Concern | Evaluation | Frequency
| Monitoring of growth development | At least every:
3 mos in infants
6 mos in older children
| Measurement of serum sodium concentration to identify unrecognized hyperosmolality early dehydration1 | At least every:
3 mos in infants
6 mos in older children
Annually in adults or only as needed, as determined on an individual basis
Kidney ultrasound exam to monitor for hydronephrosis megacystis | Annually
1. Urine output and urine specific gravity are useless as indicators of hydration status.
Source: GeneReviews — "Hereditary Nephrogenic Diabetes Insipidus"
Phenotype severity distribution: 3 always present features.
No clinical trials have been registered for diabetes insipidus, nephrogenic, X-linked.
106 publications have been identified in PubMed for diabetes insipidus, nephrogenic, X-linked. Research spans Case Report / Case Series (40%), Basic Science / Preclinical (23%), and Review / Meta-Analysis (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 42 | 40% |
Laboratory research | 24 | 23% |
Research summaries | 18 | 17% |
Testing and diagnosis research | 7 | 7% |
Disease patterns and progression | 5 | 5% |
Other research | 4 | 4% |
New treatment approaches | 4 | 4% |
Clinical study results | 2 | 2% |
Zeng Y (2026). [PMID: 41921879](https://pubmed.ncbi.nlm.nih.gov/41921879/). *Journal of affective disorders*. [Other]
Takahashi I (2026). [PMID: 41988804](https://pubmed.ncbi.nlm.nih.gov/41988804/). *Pediatr Int*. [Case Report / Case Series]
Aksoy ÖY (2026). [PMID: 41986963](https://pubmed.ncbi.nlm.nih.gov/41986963/). *J Paediatr Child Health*. [Case Report / Case Series]
Huang Y (2026). [PMID: 41982965](https://pubmed.ncbi.nlm.nih.gov/41982965/). *Transl Pediatr*. [Case Report / Case Series]
Banerjee S (2026). [PMID: 39992531](https://pubmed.ncbi.nlm.nih.gov/39992531/). *Indian journal of pediatrics*. [Diagnostic / Biomarker]
Acharya S (2026). [PMID: 41809951](https://pubmed.ncbi.nlm.nih.gov/41809951/). *European journal of case reports in internal medicine*. [Case Report / Case Series]
Yan T (2026). [PMID: 41559973](https://pubmed.ncbi.nlm.nih.gov/41559973/). *Medicine*. [Case Report / Case Series]
Dąbek M (2026). [PMID: 41598788](https://pubmed.ncbi.nlm.nih.gov/41598788/). *Journal of clinical medicine*. [Review / Meta-Analysis]
Ikegawa K (2026). [PMID: 41605691](https://pubmed.ncbi.nlm.nih.gov/41605691/). *Endocrine journal*. [Diagnostic / Biomarker]
Motomura Y (2026). [PMID: 42064718](https://pubmed.ncbi.nlm.nih.gov/42064718/). *JCEM Case Rep*. [Case Report / Case Series]